Joseph Skitzki, MD, FACS

PrintE-mail
Assistant Professor, Department of Surgical Oncology
Associate Member, Department of Immunology
Roswell Park Cancer Institute
Assistant Professor of Surgery
School of Medicine and Biomedical Sciences, State University of New York at Buffalo

Profile

Areas of Expertise: 
Melanoma
Soft tissue sarcomas
Biography: 

Joseph J. Skitzki, MD, FACS joined the faculty of Roswell Park Cancer Institute in 2009 as an Assistant Professor of Surgical Oncology and Associate Member of the Immunology Department. He is also an Assistant Professor of Surgery, School of Medicine and Biomedical Sciences, State University of New York at Buffalo.

Dr. Skitzki earned his medical degree from the Pennsylvania State University’s College of Medicine, Hershey, where he was inducted into the Alpha Omega Alpha Medical Honor Society. He completed a general surgery residency at Case Western Reserve University, Cleveland. Within his residency, Dr. Skitzki completed a two-year research fellowship in surgical oncology at the University of Michigan, Ann Arbor. He is a Diplomate of the American Board of Surgery and a Fellow in the American College of Surgeons. He holds membership in the Society of Surgical Oncology, American Society of Clinical Oncology, American Association for Cancer Research, American Society of Peritoneal Surface Malignancies, and the Association for Academic Surgery.

Dr. Skitzki is clinically active in the areas of melanoma and sarcoma with a focus on regional therapies. His independent lab focuses on immunotherapies for melanoma and animal modeling of regional therapies with the goal of clinical translation. Dr. Skitzki has authored or co-authored more than 30 journal publications, book chapters and abstracts.

Research

Research Interests: 
Immunotherapies for melanoma and animal modeling of regional therapies with the goal of clinical translation

Background Information

Education and Training: 
MD - Pennsylvania State University’s College of Medicine, Hershey
Residency: 
Surgical Residency - Case Western Reserve University, Cleveland, OH
Board Certification: 
Surgery, American Board of Surgery
Fellowships: 
Surgical Oncology Fellowship - Roswell Park Cancer Institute, Buffalo, NY
T32 Research Fellow – University of Michigan, Ann Arbor

Publications

Publications: 
  • Ito F, Seshadri M, Ong E, Alassas M, Kane JM, Skitzki JJ. Peritoneal lavage with distilled water is tumoricidal: Science or legend?. Annals of surgical oncology 2010; 17(Suppl. 1):S24-S25
  • Skitzki JJ, Repasky EA, Evans SS. Hyperthermia as an immunotherapy strategy for cancer. Current opinion in investigational drugs (London, England : 2000) 2009; 10(6):550-558
  • Evans SS, Fisher DT, Skitzki JJ, Chen Q. Targeted regulation of a lymphocyte-endothelial-interleukin-6 axis by thermal stress. International journal of hyperthermia 2008; 24(1):67-78
  • Skitzki JJ, Chen Q, Wang WC, Evans SS. Primary immune surveillance: some like it hot. Journal of molecular medicine (Berlin, Germany) 2007; 85(12):1361-1367
  • Skitzki JJ, Muhitch JB, Evans SS. Tracking the elusive lymphocyte: methods of detection during adoptive immunotherapy. Immunological investigations 2007; 36(5-6):807-827
  • Ito F, Camoriano M, Seshadri M, Evans SS, Kane JM 3rd, Skitzki JJ. Water: a simple solution for tumor spillage. Annals of surgical oncology 2011; 18(8):2357-2363
  • Skitzki J, Chen Q, Fisher D, Muhitch J, Villegas C, Kane J, Evans S. Systemic thermal therapy alters the non-permissive tumor microenvironment during adoptive immunotherapy. Annals of surgical oncology 2008; 15(Suppl. 2):96
  • Fisher DT, Chen Q, Skitzki JJ, Muhitch JB, Zhou L, Appenheimer MM, Vardam TD, Weis EL, Passanese J, Wang WC, Gollnick SO, Dewhirst MW, Rose-John S, Repasky EA, Baumann H, Evans SS. IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. Journal of clinical investigation 2011; 121(10):3846-3859
  • Francescutti V, Skitzki JJ. Sarcomas and the immune system: implications for therapeutic strategies. Surgical oncology clinics of North America 2012; 21(2):341-355
  • Barth MJ, Pendurti G, Mavis C, Czuczman N, Skitzki JJ, Hernandez-Ilizaliturri FJ, Czuczman MS. Preclinical activity of ofatumumab (OFA) in mantle cell lymphoma (MCL) in vitro, ex vivo, and in vivo models. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #e18537
  • Dawar R, Barth MJ, Mavis C, Skitzki JJ, Czuczman MS, Klener P, Hernandez-Ilizaliturri FJ. Evaluation of MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, as a novel targeted agent with single-agent antitumor activity in mantle cell lymphoma (MCL) and Hodgkin lymphoma preclinical models. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #e18539
  • Haslinger M, Kane JM, Francescutti V, Burke R, Skitzki JJ. The morbidity of cytoreduction/hyperthermic intraperitoneal chemoperfusion (HIPEC) in the modern era. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #e14172
  • Jarkowski A, Hare RB, Loud P, Skitzki JJ, Kane JM, Salerno MK, Zeitouni N, Nestico J, Vona KL, Groman AE, Khushalani NI. Systemic therapy in advanced cutaneous squamous cell carcinoma (CSCC): The Roswell Park experience : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #e19041
  • Mikucki M, Skitzki J, Fisher D, Luster A, Evans S. Obligate role of CXCR3 chemokine receptor for trafficking of effector CD8 T cells in the tumor microenvironment. Journal of immunology (Baltimore, Md. : 1950) 2012; 188:46.14
  • Shatzel J, Wooten K, Ankola A, Cheney RT, Morrison CD, Skitzki JJ. Inflammatory myofibroblastic tumor of the mesentery: a clinical dilemma. International journal of clinical oncology 2012; 17(4):380-384